Given that Nur77 modifies DC function with altered inflammatory responses, Nur77 may be an interesting therapeutic target to either boost or diminish the activation status of DCs in DC-based vaccination strategies in cancer or treatment of autoimmune diseases, respectively. Here, NR4A1 is linked to autoimmune disease.